14 results
To demonstrate that DMEK is superior to DSAEK with respect to VA.
Primary: To explore the diagnostic value to distinguish PAF and MSA of a variety of tests: corneal confocal microscopy optical coherence tomography (OCT) to measure the retinal nerve fibre layer thickness and total macular volume, corneal…
To evaluate the safety and efficacy of abicipar (2 mg), compared to 0.5 mg ranibizumab in treatment-naïve patients with neovascular AMD.
To evaluate the role of the epithelium in the effect of CXL for treatment of progressive KC and to determine whether the epithelium should be removed or can be left intact during treatment.
Primary: to evaluate the effectiveness of two treatment regimens by assessing the average stable maximum best-corrected (BCVA) change from Month 4 to Month 12 compared to Month 3. A treatment regimen will be considered a relevant treatment option if…
Primary objectiveTo assess the efficacy of intravitreally (ITV) administered VEGF Trap-Eye compared to ranibizumab (in a non-inferiority paradigm) in preventing moderate vision loss in subjects with all subtypes of neovascular AMD Secondary…
To investigate if there is an association with the R142W mutation in the RDS gene in a group of dry AMD patients from the North Limburg region
- Development of FCSPCO.- Determine if straylight is a reliable parameter for FCSPCO.
To demonstrate that FS laser aided keratoplasty for KC is superior to MALK.
To investigate whether tear biomarkers can differentiate between patients and controls, and between patient groups.
Primary To evaluate the efficacy of Pegcetacoplan compared to sham injection in patients with GA secondary to AMD assessed by change in the total area of GA lesions from baseline as measured by FAF.Key SecondaryTo evaluate the efficacy of…
To compare miLOOP assisted cataract surgery and conventional surgery with respect to the energy needed for phacoemulsification and loss of corneal endothelial cells.
In this study, we want to demonstrate that MPP is no less effective than MPP plus XRT.
Primary:• To demonstrate that RTH258 6 mg is not inferior to aflibercept 2 mg with respect to the change in best-corrected visual acuity (BCVA) from Baseline to Week 48Secondary:• To demonstrate that RTH258 6 mg is not inferior to aflibercept 2 mg…